More information: Komal L. Jhaveri et al, Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2501796 Journal ...

Credit: Getty Images Repose Gray by Sherwin-Williams and Revere Pewter by Benjamin Moore are two of the most popular neutral shades. They are best sellers from both brands and loved by designers ...

A first-line regimen combining encorafenib, cetuximab, and mFOLFOX6 significantly increases progression-free survival (12.8 vs. 7.1 months) and overall survival (30.3 vs. 15.1 months) compared to ...

The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET ...

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and ...

The addition of olaparib to neoadjuvant chemotherapy improved overall survival in BRCA-mutated breast cancer, despite no improvement in pathologic response. Adding the PARP inhibitor led to a 3 ...

Outcomes of older matched sibling donors compared to younger matched unrelated donors in allogeneic hematopoietic cell transplantation for AML in first complete remission. This is an ASCO Meeting ...

Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.

Relay Therapeutics announced updated interim clinical data for RLY-2608, an investigational inhibitor of PI3Kα designed for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated ...